The Emergency Awards RADx-RAD program offers this grant to develop innovative, non-traditional approaches for identifying SARS-CoV-2 and other COVID-19 biomarkers. This grant is for creating portable biosensing devices targeting skin or the oral cavity for symptomatic and asymptomatic COVID-19 detection. For skin, devices like E-nose (SCENT program) will detect volatile organic compounds. For the oral cavity, technologies will sample biosignatures from breath, saliva, or tissues. The aim is to advance novel, safe, and effective biosensing technologies with integrated AI systems for the detection, diagnosis, prediction, prognosis, and monitoring of COVID-19 in various settings, emphasizing non-invasive, real-time measurements for current and future pandemics.
Opportunity ID: 328569
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-OD-20-020 |
| Funding Opportunity Title: | Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 06, 2020 |
| Last Updated Date: | Aug 06, 2020 |
| Original Closing Date for Applications: | Sep 18, 2020 |
| Current Closing Date for Applications: | Sep 18, 2020 |
| Archive Date: | Oct 24, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-020.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00262929 | Aug 18, 2020 | Sep 18, 2020 | View |
Package 1
Mandatory forms
328569 RR_SF424_2_0-2.0.pdf
328569 PHS398_CoverPageSupplement_5_0-5.0.pdf
328569 RR_OtherProjectInfo_1_4-1.4.pdf
328569 PerformanceSite_2_0-2.0.pdf
328569 RR_KeyPersonExpanded_2_0-2.0.pdf
328569 RR_Budget_1_4-1.4.pdf
328569 PHS398_ResearchPlan_4_0-4.0.pdf
328569 SBIR_STTR_Information_1_3-1.3.pdf
328569 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
328569 RR_SubawardBudget30_1_4-1.4.pdf
328569 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
